Article Text

Download PDFPDF
Haematopoietic stem cell transplantation (HSCT) in a patient with Sjögren's syndrome and lung malt lymphoma cured lymphoma not the autoimmune disease
  1. G FERRACCIOLI,
  2. R DAMATO,
  3. S DE VITA
  1. R FANIN,
  2. D DAMIANI,
  3. M BACCARANI
  1. Division of Rheumatology
  2. Udine Medical School
  3. University of Udine
  4. 33100 Udine, Italy
  5. Division of Haematology
  6. Udine Medical School
  1. gf.ferraccioli{at}med.uniud.it gianfranco.ferraccioli{at}dpmsc.uniud.it

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Haematopoietic stem cell transplantation (HSCT) has been used in an attempt to control autoimmune diseases that respond poorly to conventional treatment, or as a way of readjusting the immunological balance.1 As far as we know, only one case of primary Sjögren's (SS) has been reported,2 with an unfavourable outcome. Another patient received an allogeneic bone marrow transplant and also had an unfavourable outcome.3 We describe here a further patient with primary SS who underwent HSCT for a non-Hodgkin's lymphoma affecting the lung (large cell, mucosa associated lymphoid tissue (MALT) lymphoma) and review the literature on the effects of HSCT on the autoimmune features and histopathological changes in primary SS.

Case report

A white woman, aged 42, developed recurrent parotid swelling and symptomatic sicca syndrome, with a Schirmer's test I of 5 mm in the right eye and 4 mm in the left eye. Break up time was 6 s and sialometry was <1 ml.

She had periodic relapses of her parotid swelling. In August 1994 (aged 57) lung x rays …

View Full Text